Sulisatin (also known as DAN-603) is an indolinone derivative patented by Andreu, Dr., S. A. as a laxative. In preclinical models, Sulisatin increases selectively the colon motility without modifying the speed of gastric, intestinal (small intestine) and caecal emptying in rats. Sulisatin is unable to inhibit water absorption in rat colon while small amounts of Sulisatin may inhibit it significantly.

Ponfibrate is clofibrate derivative. It is an antilipidemic agent with demonstrated hypobetalipoproteinemic effect.

Canosimibe is diphenyl azetidinone patented by German pharmaceutical company Aventis Pharma Deutschland GmbH as hypolipidemic agent. Canosimibe acts as pre-systemic inhibition of intestinal cholesterol absorption. Unfortunately, during phase II clinical trials Canosimibe failed to demonstrate efficacy in in patients with primary severe hypercholesterolemia.

Pemaglitazar was developed as a dual peroxisome proliferator-activated receptors alpha and gamma (PPAR- α,γ) agonist. Information about the further development of this drug is not available.

Glutamine, a hypoglycemic agent that was studied to treat diabetes. Information about the current use of this compound is not available.

Hexacyprone has been used as a choleretic agent. Information about the current use of this compound is not available.

Etoformin is an antidiabetic drug. It decreases gluconeogenesis and increases peripheral utilization of glucose.

Dulofibrate is a fibrate derivative with antilipidemic activity. Unlike clofibrate, dulofibrate is selective for a reduction in triglycerides. Dulofibrate decreased the conjugation of nopol. Dulofibrate exhibited a clofibrate-like effect on the induction of hepatic drug-metabolizing enzymes, characterized by an increase in lauric acid 12-hydroxylation and bilirubin UDP-glucuronosyltransferase activities. Dulofibrate and fenofibrate have been shown to possess an equal potency as peroxisome proliferators.

Lipoprotein lipase (LPL) is a rate-limiting enzyme that hydrolyzes circulating triglyceride-rich lipoproteins such as very low-density lipoproteins and chylomicrons. Otsuka Pharmaceutical Factory, Inc. synthesized the LPL activator NO-1886 (ibrolipim, [4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester, CAS 133208-93-2). NO-1886 increased LPL mRNA and LPL activity in adipose tissue, myocardium and skeletal muscle, resulting in an elevation of postheparin plasma LPL activity and LPL mass. It was discovered, that this agent has a potentially beneficial for the treatment of hypertriglyceridemia, hypo-HDL cholesterolemia, and protection from atherosclerosis. In addition, this agent may be used in the treatment of obesity and obesity-linked health problems in postmenopausal women.

Proxifezone is a mixture of phenylbutazone and d-propoxyphene patented by Societe d'Etudes de Recherches et d'Applications Scientifiques et Medicales E.R.A.S.M.E. as an anti-inflammation pharmaceutical composition with potent analgesic activity. Anti-inflammatory effects of Proxifezone associated with Phenylbutazone, that acts as a nonsteroidal anti-inflammatory drug (NSAID). D-propoxyphene acts as an opioid analgesic, that provides strong pain relief.